A Randomized, Subject and Investigator Blinded, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis
收藏DataCite Commons2025-12-16 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012408/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The main purpose of this phase 2 study was to assess the efficacy and safety of CMK389 in patients with atopic dermatitis.
提供机构：
Vivli
创建时间：
2025-12-16
